GEHC · Insider Trading
GE HealthCare Technologies Inc. Common Stock
Every open-market purchase and sale reported by GEHC officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-16 | William K Grogan | Chief Financial Officer | A | +75,096 | — |
| 2026-09-04 | Philip Rackliffe | CEO, AIS | F | −798 | −$56.31K |
| 2026-09-04 | Taha Kass-Hout | Chief Technology Officer | F | −1,502 | −$105.98K |
| 2026-09-04 | Catherine Estrampes | Chief Commer. & Growth Officer | F | −508 | −$35.84K |
| 2026-09-04 | Adam Y Holton | Chief People Officer | F | −673 | −$47.49K |
| 2026-09-04 | Peter J Arduini | President and CEO | F | −6,303 | −$444.74K |
| 2026-09-04 | George A. Newcomb | Chief Accounting Officer | F | −112 | −$7.90K |
| 2026-09-04 | Frank R Jimenez | GC & Corporate Secretary | F | −1,480 | −$104.43K |
| 2026-09-04 | Kevin Michael O'Neill | CEO, PDx | F | −718 | −$50.66K |
| 2026-09-03 | Adam Y Holton | Chief People Officer | F | −659 | −$46.94K |
| 2026-09-03 | Philip Rackliffe | CEO, AIS | F | −856 | −$60.97K |
| 2026-09-03 | Jeannette Bankes | CEO, Patient Care Solutions | F | −1,064 | −$75.79K |
| 2026-09-03 | Taha Kass-Hout | Chief Technology Officer | F | −2,940 | −$209.42K |
| 2026-09-03 | Frank R Jimenez | GC & Corporate Secretary | F | −3,131 | −$223.02K |
| 2026-09-03 | Peter J Arduini | President and CEO | F | −11,515 | −$820.21K |
| 2026-08-18 | Adam Y Holton | Chief People Officer | F | −1,360 | −$100.22K |
| 2026-05-26 | Kevin Lobo | Director | Buy | +10,000 | +$641.80K |
| 2026-05-19 | Jeannette Bankes | CEO, Patient Care Solutions | F | −5,535 | −$346.88K |
| 2026-05-19 | Philip Rackliffe | CEO, AIS | A | +16,458 | — |
| 2026-05-13 | Rodney F Hochman | Director | Buy | +1,618 | +$100.36K |
| 2026-05-11 | William J Stromberg | Director | A | +3,586 | — |
| 2026-05-11 | Anne T Madden | Director | A | +5,868 | — |
| 2026-05-11 | Kevin Lobo | Director | A | +3,586 | — |
| 2026-05-11 | Catherine A Lesjak | Director | A | +3,586 | — |
| 2026-05-11 | Rodney F Hochman | Director | A | +6,275 | — |
| 2026-05-11 | H Lawrence Culp Jr | Director | A | +7,743 | — |
| 2026-05-11 | Watkin Phoebe L. Yang | Director | MIXED | +4,586 | +$63.01K |
| 2026-05-07 | William J Stromberg | Director | Buy | +1,000 | +$61.69K |
| 2026-05-07 | H Lawrence Culp Jr | Director | Buy | +80,805 | +$5.00M |
| 2026-05-01 | James Saccaro | Chief Financial Officer | Buy | +3,310 | +$200.59K |
| 2026-04-30 | Peter J Arduini | President and CEO | Buy | +4,169 | +$249.83K |
| 2026-04-30 | Frank R Jimenez | GC & Corporate Secretary | Buy | +1,750 | +$105.79K |
| 2026-03-17 | Kevin Lobo | Director | A | +777 | — |
| 2026-03-04 | Peter J Arduini | President and CEO | A | +49,120 | — |
| 2026-03-04 | James Saccaro | Chief Financial Officer | A | +12,475 | — |
| 2026-03-04 | Roland Rott | CEO, Imaging | A | +8,576 | — |
| 2026-03-04 | Philip Rackliffe | CEO, AVS | A | +9,356 | — |
| 2026-03-04 | Kevin Michael O'Neill | CEO, PDx | A | +6,549 | — |
| 2026-03-04 | George A. Newcomb | Chief Accounting Officer | A | +1,309 | — |
| 2026-03-04 | Adam Y Holton | Chief People Officer | A | +5,457 | — |
| 2026-03-04 | Taha Kass-Hout | Chief Technology Officer | A | +13,254 | — |
| 2026-03-04 | Frank R Jimenez | GC & Corporate Secretary | A | +10,915 | — |
| 2026-03-04 | Jeannette Bankes | CEO, Patient Care Solutions | A | +6,861 | — |
| 2026-02-17 | Peter J Arduini | President and CEO | MIXED | +41,463 | −$2.65M |
| 2026-02-17 | James Saccaro | Chief Financial Officer | MIXED | +14,040 | −$678.74K |
| 2026-02-17 | Frank R Jimenez | GC & Corporate Secretary | MIXED | +13,721 | −$661.87K |
| 2026-02-17 | Taha Kass-Hout | Chief Technology Officer | MIXED | +15,552 | −$616.73K |
| 2026-02-17 | Roland Rott | CEO, Imaging | MIXED | +3,942 | −$312.29K |
| 2026-02-17 | Philip Rackliffe | CEO, AVS | MIXED | +1,980 | −$92.98K |
| 2026-02-17 | Kevin Michael O'Neill | CEO, PDx | MIXED | +3,677 | −$258.27K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| H Lawrence Culp Jr | Director | 344,553 | $24.50M |
| Peter J Arduini | President and CEO | 241,606 | $17.18M |
| Frank R Jimenez | GC & Corporate Secretary | 89,321 | $6.35M |
| Taha Kass-Hout | Chief Technology Officer | 88,467 | $6.29M |
| James Saccaro | Chief Financial Officer | 87,471 | $6.22M |
| William K Grogan | Chief Financial Officer | 62,256 | $4.43M |
| Philip Rackliffe | CEO, AIS | 41,533 | $2.95M |
| Roland Rott | CEO, Imaging | 41,082 | $2.92M |
| Kenneth R. Stacherski | Chief Enterprise Oper. Officer | 40,996 | $2.92M |
| Jeannette Bankes | CEO, Patient Care Solutions | 37,293 | $2.65M |
| Kevin Michael O'Neill | CEO, PDx | 32,085 | $2.28M |
| Catherine Estrampes | Chief Commer. & Growth Officer | 23,573 | $1.68M |
| Rodney F Hochman | Director | 21,504 | $1.53M |
| Adam Y Holton | Chief People Officer | 19,533 | $1.39M |
| Anne T Madden | Director | 19,479 | $1.39M |
| William J Stromberg | Director | 18,916 | $1.35M |
| Thomas J. Westrick | CEO, Patient Care Solutions | 18,501 | $1.32M |
| Kevin Lobo | Director | 14,363 | $1.02M |
| Watkin Phoebe L. Yang | Director | 13,702 | $974.35K |
| Catherine A Lesjak | Director | 12,702 | $903.24K |
| George A. Newcomb | Chief Accounting Officer | 10,527 | $748.57K |
| Risa J Lavizzo-Mourey | Director | 10,157 | $722.26K |
| Tomislav Mihaljevic | Director | 9,116 | $648.24K |
| Lloyd Howell Jr | Director | 9,116 | $648.24K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the GEHC quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.